Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.

Published

Journal Article (Review)

The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.

Full Text

Duke Authors

Cited Authors

  • Doraiswamy, VA; Slepian, MJ; Gesheff, MG; Tantry, US; Gurbel, PA

Published Date

  • September 2013

Published In

Volume / Issue

  • 11 / 9

Start / End Page

  • 1259 - 1267

PubMed ID

  • 23968500

Pubmed Central ID

  • 23968500

Electronic International Standard Serial Number (EISSN)

  • 1744-8344

Digital Object Identifier (DOI)

  • 10.1586/14779072.2013.827469

Language

  • eng

Conference Location

  • England